Premium
Improvement of liver function and non‐invasive fibrosis markers in hepatitis B virus‐associated cirrhosis: 2 years of entecavir treatment
Author(s) -
Shin Seung Kak,
Kim Jeong Han,
Park Hyeonsu,
Kwon Oh Sang,
Lee Hyun Jung,
Yeon Jong Eun,
Byun Kwan Soo,
Suh Sang Jun,
Yim Hyung Joon,
Kim Yun Soo,
Kim Ju Hyun
Publication year - 2015
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.13020
Subject(s) - entecavir , medicine , gastroenterology , cirrhosis , liver function , aspartate transaminase , hepatitis b virus , liver disease , hepatitis b , alanine transaminase , fibrosis , virus , immunology , lamivudine , alkaline phosphatase , biochemistry , chemistry , enzyme
Background and Aim Entecavir (ETV) induces biochemical and histologic improvement of the liver in patients with chronic hepatitis B. This study aimed to confirm that 2 years of ETV treatment improves liver function and non‐invasive fibrosis markers in patients with hepatitis B virus (HBV)‐associated cirrhosis. Methods A total 472 naïve patients with HBV‐associated cirrhosis was treated with ETV for at least 2 years, between March 2007 and December 2012. Model for end‐stage liver disease and Child‐Pugh (CP) score were used to evaluate the improvement of liver function. Aspartate transaminase to platelet ratio index, FIB‐4 index, and fibrosis index were used to evaluate the improvement of fibrosis. Results The final 370 of 472 patients with HBV‐associated cirrhosis were enrolled. Mean age was 51 ± 10 years, and 240 patients (64.9%) were men. The distribution of CP class was 71.1% in A, 24.6% in B, and 4.3% in C. Mean end‐stage liver disease and CP score changed over the study period from 8.5 ± 4.6 to 6.2 ± 4.2 ( P < 0.001) and from 6.2 ± 1.6 to 5.6 ± 0.9 ( P < 0.001), respectively. Aspartate transaminase to platelet ratio index, FIB‐4 index, and fibrosis index changed from 3.6 ± 4.5 to 1.5 ± 1.5 ( P < 0.001), from 7.0 ± 6.2 to 3.9 ± 2.8 ( P < 0.001), and from 3.3 ± 0.9 to 2.5 ± 1.1 ( P < 0.001), respectively. Conclusions After 2 years of treatment, ETV improves liver function and non‐invasive fibrosis markers in patients with HBV‐associated cirrhosis.